Timiperone
CAS: 57648-21-2
Ref. 3D-FT28279
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
- 4-[4-(2,3-Dihydro-2-thioxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone
- 1-(4-Fluorophenyl)-4-[4-(2-thioxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]butan-1-one
- 1-[1-[3-(4-Fluorobenzoyl)propyl]-4-piperidyl]-2,3-dihydrobenzimidazole-2-thione
- 1-[1-[3-(4-Fluorobenzoyl)propyl]-4-piperidyl]-2-mercaptobenzimidazole
- 1-butanone, 4-[4-(2,3-dihydro-2-thioxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(4-fluorophenyl)-
- 260-880-9
- 4-Fluoro-4-[4-(2-thioxo-1-benzimidazolinyl)piperidino]butyrophenone
- Celmanil
- Dd 3480
- Timeperone
- See more synonyms
- Tolopelon
Timiperone is a drug that acts as an absorption enhancer, which is used in the treatment of inflammatory bowel disease. It inhibits the production of serum prolactin levels and cb2 receptor, which may be related to its anti-inflammatory effects. Timiperone has been shown to have anti-inflammatory effects in vivo in a model of intestinal inflammation. It prevents intestinal damage by inhibiting the release of pro-inflammatory cytokines from macrophages and T cells, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Timiperone also prevents the proliferation of neutrophils and eosinophils. This drug also has inhibitory effects on dopamine uptake and synthesis in rats with experimental bowel disease. The symptoms of this condition are reduced with timiperone treatment.
